2. Search Result
Search Result
Results for "

MSC

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

7

Peptides

4

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148518
    MSC-1186

    		SRPK Cancer
    MSC-1186 is a highly selective pan-SRPK inhibitor. MSC-1186 has activity for SRPK1, SRPK2 and SRPK3 with IC50 values of 2.7 nM, 81 nM and 0.6 nM, respectively. MSC-1186 can be used for the research of cancer .
    <em>MSC</em>-1186
  • HY-147208
    MSC-4106

    		YAP Cancer
    MSC-4106 is an orally active and potent inhibitor of YAP/TAZ-TEAD. MSC-4106 inhibits TEAD1 or TEAD3 auto-palmitoylation and shows inhibitory effect on NCI-H226 tumor xenograft model .
    <em>MSC</em>-4106
  • HY-132301
    MSC-4381

    MCT4-IN-1

    		 Monocarboxylate Transporter Cancer
    MSC-4381 (MCT4-IN-1) is an orally active and selective monocarboxylate transporter 4 (MCT4/SLC16A3) inhibitor with an IC50 of 77 nM and a Ki of 11 nM. MSC-4381 targets to the cytosolic domain of MCT4. MSC-4381 results in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells. MSC-4381 has the potential for MCT4 transporter inhibition research . MSC-4381 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>MSC</em>-4381
  • HY-123872
    MSC1094308

    		p97 Cancer
    MSC1094308 is a non-competitive and reversible VPS4B/p97 (VCP) (I/II type AAA ATPase) allosteric inhibitor, with IC50 values of 0.71 μM and 7.2 μM for VPS4B and p97, respectively . MSC1094308 inhibits the D2 ATPase activity by binding to a agentable hotspot of p97. MSC1094308 can be used in study of cancer .
    <em>MSC</em>1094308
  • HY-110262
    MSC 2032964A

    		p38 MAPK Inflammation/Immunology
    MSC 2032964A is an orally active, selective inhibitor for apoptosis signal-regulating kinase 1(ASK1) with IC50 of 96 nM. MSC 2032964A preserves the visual responses in EAE mice model and exhibits potency in ameliorating the neuroinflammation .
    <em>MSC</em> 2032964A
  • HY-123851
    MSC2504877

    M2912

    		 PARP Cancer
    MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC50s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity .
    <em>MSC</em>2504877
  • HY-101611
    MSC2530818

    		CDK Cancer
    MSC2530818 is a potent, selective and orally available CDK8 inhibitor with an IC50 of 2.6 nM for CDK8.
    <em>MSC</em>2530818
  • HY-RS08707
    MSC Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MSC Human Pre-designed siRNA Set A contains three designed siRNAs for MSC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MSC Human Pre-designed siRNA Set A
    MSC Human Pre-designed siRNA Set A
  • HY-135827
    Roginolisib

    MSC2360844; IOA-244

    		 PI3K Inflammation/Immunology Cancer
    Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases .
    Roginolisib
  • HY-135827A
    Roginolisib hemifumarate

    MSC2360844 hemifumarate; IOA-244 hemifumarate

    		 PI3K Inflammation/Immunology Cancer
    Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases .
    Roginolisib hemifumarate
  • HY-100501
    M2698

    MSC2363318A
    M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity .
    M2698
  • HY-12042
    Pimasertib
    5+ Cited Publications

    AS703026; MSC1936369B

    		 MEK Cancer
    Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available MEK1/2 inhibitor .
    Pimasertib
  • HY-101215
    Evobrutinib
    5+ Cited Publications

    M2951; MSC2364447C
    Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases .
    Evobrutinib
  • HY-N0008
    Orcinol glucoside

    		Wnt Neurological Disease
    Orcinol glucoside (OG) is an active constituent isolated from Curculigo orchioides, with antidepressant effects. Orcinol glucoside facilitates the shift of MSC fate to osteoblast and prevents adipogenesis via Wnt/β-catenin signaling pathway .
    Orcinol glucoside
  • HY-P1410
    GsMTx4
    Maximum Cited Publications
    28 Publications Verification

    		 TRP Channel Piezo Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    GsMTx4 is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
    GsMTx4
  • HY-P1410A
    GsMTx4 TFA
    Maximum Cited Publications
    28 Publications Verification

    		 TRP Channel Piezo Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    GsMTx4 TFA is a spider venom peptide that selectively inhibits cationic-permeable mechanosensitive channels (MSCs) belonging to the Piezo and TRP channel families. GsMTx4 TFA also blocks cation-selective stretch-activated channels (SACs) , attenuates lysophosphatidylcholine (LPC)-induced astrocyte toxicity and microglial reactivity. GsMTx4 TFA is an important pharmacological tool for identifying the role of these excitatory MSCs in normal physiology and pathology .
    GsMTx4 TFA
  • HY-126225
    SJA710-6

    		Others Metabolic Disease
    SJA710-6 is a small molecule able to selectively differentiate MSCs toward hepatocyte-like cells .
    SJA710-6
  • HY-P1410B
    D-GsMTx4

    		Piezo Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    D-GsMTx4, a spider peptide, is the D-enantiomer of GsMTx4 (HY-P1410). D-GsMTx4 inhibits the mechanosensitive ion channel Piezo2. D-GsMTx4 can be used for research of mechanical stress .
    D-GsMTx4
  • HY-P1410C
    D-GsMTx4 TFA

    		Piezo Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    D-GsMTx4 TFA, a spider peptide, is the D-enantiomer of GsMTx4 (HY-P1410). D-GsMTx4 TFA inhibits the mechanosensitive ion channel Piezo2. D-GsMTx4 TFA can be used for research of mechanical stress .
    D-GsMTx4 TFA
  • HY-108438
    TCS 2210

    		Others Neurological Disease
    TCS 2210 (compound 1) is a neuronal differentiation inducer in mesenchymal stem cells (MSCs). TCS 2210 increases expression of the neuronal markers β-III tubulin and neuron-specific enolase (NSE) .
    TCS 2210
  • HY-113568
    CAY10581

    		Indoleamine 2,3-Dioxygenase (IDO) Cancer
    CAY10581, a pyranonaphthoquinone derivative, is a highly specific and reversible uncompetitive IDO Inhibitor with an IC50 of 55 nM .
    CAY10581
  • HY-153332
    Tankyrase-IN-5

    		PARP Cancer
    Tankyrase-IN-5 (Compound 30f), an analogue of MSC2504877 (HY-123851), is a tankyrase TNKS1 and TNKS2 inhibitor with IC50s of 2.3 nM and 7.9 nM, respectively .
    Tankyrase-IN-5
  • HY-N8917
    (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane

    		Phosphatase Metabolic Disease
    (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane is a homoisoflavonoid. (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane increases the level of alkaline phosphatase (ALP) activity. (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane promotes mesenchymal stem cells (MSCs) osteogenesis, but cannot enhance MSCs proliferation. (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane can be used for osteoporosis research .
    (3R)-7-hydroxy-3-(4-hydroxybenzyl)chromane
  • HY-N0898A
    (-)-Catechin

    (-)-Cianidanol; (-)-Catechuic acid

    		 COX Cancer
    (-)-Catechin is Catechin's one kind of different structure. Catechin inhibitory enzyme-1 (COX-1), IC50 为 1.4 μM. (-)-Catechin promotes hBM-MSC adipose cell differentiation, increases fat cell differentiation, and PPARγ level.
    (-)-Catechin
  • HY-147511
    PPARγ agonist 7

    		PPAR Others
    PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of PPARγ. PPARγ agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC50, 4.34 μM) .
    PPARγ agonist 7
  • HY-110218
    CW 008

    		PKA Epigenetic Reader Domain Others
    CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion .
    CW 008
  • HY-108628
    SU16f
    1 Publications Verification

    		 PDGFR Cancer
    SU16f is a potent and selective PDGFRβ inhibitor with IC50s of 10 nM, 140 nM, 2.29 μM for PDGFRβ, PDGFR1, PDGFR2, respectively . Neutralization of PDGFRβ receptor by SU16f blocks the promoting role of GC-MSCs (gastric cancer-derived mesenchymal stem cells) conditioned medium in gastric cancer cell proliferation and migration .
    SU16f
  • HY-131032
    KI-7

    		Adenosine Receptor Others
    KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC50=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC50s of 2390 nM and 2550 nM, respectively .
    KI-7
  • HY-B1890
    (±)-Catechin
    1 Publications Verification

    rel-Cianidanol; rel-Catechuic acid

    		 COX Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    (±)-Catechin (rel-Cianidanol) This is a green tea polyester. Catechin possesses anti-cancer activity, which has led to its demise. (±)-Catechin 具有两种forms (+)-Catechin and its reflection body (-)-Catechin. (+)-Catechin inhibitory environment-1 (COX-1) IC50 为 1.4 μM. (-)-Catechin has the effect of promoting hBM-MSC adipose cell differentiation, increasing adipose tissue, and PPARγ horizontal. (±)-Catechin has anti-diabetic, anti-hypertrophic, anti-diabetic, anti-cardiovascular, anti-infective, and liver-protecting effects.
    (±)-Catechin
  • HY-160053
    Gint4.T aptamer sodium

    		PDGFR Cancer
    Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .
    Gint4.T aptamer sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: